Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial

Ivor Benjamin, MD
OncoLink Assistant Editor
Last Modified: May 21, 2000

Presenter: Hugh Walker
Affiliation: Queens Univ. and Tom Baker Cancer Ctr, Canada

Background:
This sub-analysis of 160 patients in the intergroup trial (EORTC-GCCG, NOCOVA, NCIC-CTG, SGCSG) compares the cost effectiveness of paclitaxel (Taxol) - cisplatin (TP) vs. cyclophosfamide-cisplatin in the treatment of epithelial ovarian cancer.

Materials and Methods:

  • 160 of 680 patients originally randomized to receive TP vs. CP were analyzed for cost comparison.
  • The study group were the patients randomized by the NCIC-CTG in the original trial.
  • Cost-effectiveness (CE) defined as incremental cost per incremental life-year gained) based on median overall survival in Canadian patients.
Results:
  • CE was $13,135 (US Dollars) for TP vs. CP
  • The gross cost per progression-free life year gained on the TP arm was $21,321
Authors' Conclusions
  • CE for the gain in overall survival from TP is well below the commonly cited threshold for cost-effective care of $50,000 per incremental life-year of overall survival.
  • TP has acceptable CE in the treatment of epithelial ovarian cancer
Clinical/Scientific Implications:
  • When compared with other life-extending therapies (e.g. renal dialysis) TP is cost effective
  • Oncologists treating ovarian cancer patients with TP may wish to cite this study if their patients are denied reimbursement by health insurance providers.

ASCO Abstract 1501

Blogs

Is Ayurveda the Answer to Women’s Health Issues?
by The 4Wholeness Team
September 01, 2015